Daewon Pharmaceutical Launches 'Tolvis Tablets' for Kidney Disease Treatment

Daewon Pharmaceutical's ADPKD treatment 'Tolvis Tab' (Photo by Daewon Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] Daewon Pharmaceutical announced on the 24th that it has launched 'Tolvis Tablets,' a treatment for autosomal dominant polycystic kidney disease (ADPKD).

Tolvis Tablets contain tolvaptan, an active ingredient that blocks the action of the antidiuretic hormone vasopressin. They are available in two dosages: 15 mg and 30 mg. The prices are set at 6,539 KRW and 6,554 KRW, respectively.

ADPKD is a hereditary disease occurring in approximately 1 in 1,000 people. After reaching adulthood, numerous cysts develop in both kidneys, leading to decreased kidney function and eventually kidney failure. Symptoms may include high blood pressure, hematuria, abdominal pain, back and flank pain, and abdominal bloating. Since it is an autosomal dominant genetic disorder, if one parent has the disease, there is a 50% chance of inheritance by children regardless of gender.

Tolvis Tablets help suppress cyst formation and decline in kidney function in ADPKD patients, thereby delaying the progression to end-stage renal disease.

Additionally, by blocking the action of vasopressin, pure water is excreted in the urine without electrolyte loss, which can increase serum sodium concentration and be used to treat hyponatremia. Hyponatremia occurs when there is excess water in the body. This disrupts fluid balance and can cause symptoms such as headaches and nausea. In severe cases, water enters brain cells, leading to neurological symptoms such as mental disorders, consciousness impairment, and seizures.

A Daewon Pharmaceutical official stated, "ADPKD patients often need to take tolvaptan for a long period. Tolvis Tablets are expected to reduce the financial burden on patients with their economical pricing and expand treatment opportunities."

This content was produced with the assistance of AI translation services.